Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Xenetic Biosciences, Inc. (XBIO)

Xenetic to acquire Santersus AG in all-stock deal; Santersus holders to own about 85%

Mixed Impact 5 of 5 m&a Written later

Xenetic Biosciences agreed on September 14, 2026 to acquire all share capital of Swiss company Santersus AG in exchange for newly issued Xenetic common stock, subject to Xenetic stockholder approval and other conditions. On a pro forma basis, existing Xenetic equity holders would own about 15.0% of the combined company and Santersus equity holders about 85.0%, subject to adjustment based on Xenetic's net cash at closing, so current shareholders' stake would be substantially diluted.

Key points

  • Santersus equity holders expected to own about 85.0% and Xenetic equity holders about 15.0% of the combined company on a fully diluted basis.
  • Closing is expected in the fourth quarter of 2026, subject to stockholder approval, Nasdaq listing approval and an effective Form S-1 resale registration statement.
  • Xenetic may owe Santersus a $500,000 termination fee under specified circumstances; either party may reimburse the other for fees and expenses up to $300,000.
  • The combined company would be renamed Santersus Bio, Inc. with an eight-member board, six designated by Santersus, and expected to trade under the symbol SNTS.

The filing

CompanyXenetic Biosciences, Inc. (XBIO)
Form8-K, current report
Filed with the SECSep 16, 2026, 7:00 AM ET
Accession number0001683168-26-007181

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.